o b

MS Community Hails New FDA Approved Drug

Aimee Sharp
Author | Shield HealthCare
05/16/17  10:48 AM PST
FDA Approved Drug

By Libby Smith for CBS Denver

LAKEWOOD, Colo (CBS4) – The Food and Drug Administration recently approved a new drug to treat multiple sclerosis, and many in the MS community are calling it a game changer.

“It’s great,” said Anuska Ullal, a progressive MS patient.

Ullal is thrilled about this new drug, because it’s the first approved treatment for progressive MS. When she was diagnosed with the disease nine years ago, Ullal says there were only four approved treatments. Now there are 15 drugs to treat MS, including this first one for progressive.

“It’s just slowing it down, I just need it to slow down,” Ullal told CBS4.

This Colorado mom has a four-and-a-half year old, and plenty she still wants to do.

“There’s kind of a sense of urgency for me to kind of go down a list of things I want to get done,” Ullal explained.

The disease is beginning to affect her legs. Multiple sclerosis is an autoimmune disease in which the protective covering of the nerves is destroyed. MS is different for every patient. Ullal struggles with tingling in her face and all over her body, terrible headaches, and lots of pain.

“I can’t feel my left leg from my knee down. Now, I’m not being able to feel my right leg as well,” Ullal explained.

In Dallas, Texas, Mike Miller is one of the first patients to receive the new drug. It’s called Ocrevus, and it kills the immune cells that cause the disease. He’s hopeful Ocrevus will be a game changer.

“It had the fewest serious health problems of any drug that we’ve studied,” said Dr. Timothy Vollmer, a neurologist with the Rocky Mountain MS Center.

Ocrevus is an infusion that patients take twice a year. It slows down the progression of the disease; it decreases the number of new lesions on the brain; and helps the body repair the damage done by MS.

Read the Full Article at CBS Denver.

Trending
Recent Colorado
Comments

Leave a comment

Your email address will not be published. Required fields are marked *